GSK Shares Dip 0.34% Rank 425th in Volume with $0.3B Trade as FDA Approves Leucovorin for Rare Disorder

Market Snapshot

On March 10, 2026, shares of GlaxoSmithKline (GSK) closed with a 0.34% decline, marking a modest pullback in a trading session where the stock ranked 425th in volume, with a total trading value of $0.30 billion. The decline, while slight, reflects mixed investor sentiment ahead of the U.S. Food and Drug Administration’s (FDA) approval of leucovorin for a rare genetic disorder. The stock’s performance suggests caution amid regulatory developments and broader market dynamics, as the news both validated and tempered expectations for GSK’s involvement in the autism-linked treatment landscape.

Key Drivers

The FDA’s approval of leucovorin for cerebral folate deficiency caused by a rare genetic variant (CFD-FOLR1) represents a pivotal but narrowly defined milestone for GSK. The drug, marketed as Wellcovorin, is now the first treatment for this ultra-rare condition, which affects fewer than 1 in a million individuals. However, the approval notably excluded broader autism spectrum disorder (ASD) applications, a key area of prior optimism. This decision followed a high-profile September 2025 White House event where President Trump and Health Secretary Robert F. Kennedy Jr. promoted leucovorin as a potential therapy for autism, sparking a 71% surge in pediatric prescriptions in subsequent months. The FDA’s retreat from these broader claims, citing insufficient evidence from small, heterogeneous studies, underscored the agency’s adherence to rigorous scientific standards despite political pressure.

The approval process itself diverged from traditional clinical trial-based pathways, relying instead on a systematic review of case reports and mechanistic data. This approach, while necessary due to the rarity of CFD-FOLR1 (with only 20–50 documented cases globally), has sparked debate within the medical community. Critics, including the American Academy of Pediatrics, have long cautioned against off-label use of leucovorin for autism, emphasizing the lack of robust evidence. The FDA’s decision to prioritize real-world evidence for ultra-rare diseases aligns with evolving regulatory frameworks but highlights the challenges of balancing innovation with patient safety in niche therapeutic areas.

GSK’s strategic position in this development is complex. While the company no longer manufactures Wellcovorin, the FDA’s expanded label now applies to all generic versions of leucovorin, potentially increasing market access. This shift may mitigate revenue risks for GSK, which exited the drug’s production in the 1990s. However, the narrower approval could limit the drug’s commercial upside compared to the initial hype around autism applications. The FDA’s encouragement for increased generic production further underscores the agency’s focus on affordability and supply stability, which could indirectly benefit GSK by maintaining market confidence in leucovorin’s role in rare disease treatment.

The stock’s 0.34% decline on the day of the announcement likely reflects investor recalibration of expectations. While the FDA’s action validated leucovorin’s efficacy in CFD-FOLR1—a condition with limited but unmet medical need—it failed to deliver the broader autism approval that had driven earlier enthusiasm. The mixed signals—scientific validation for a niche indication versus regulatory caution for a larger market—likely contributed to the muted market reaction. Additionally, the retraction of a key 2024 study supporting autism benefits earlier in 2026 may have tempered investor optimism, reinforcing the FDA’s stance that larger trials are necessary for broader applications.

Looking ahead, the approval sets a precedent for regulatory flexibility in ultra-rare diseases, potentially influencing future approvals of similar therapies. However, GSK’s role in this space appears constrained by its decision to exit leucovorin production. The company’s focus on other therapeutic areas, such as vaccines and respiratory treatments, may now take precedence in investor assessments. For now, the leucovorin saga illustrates the interplay of regulatory rigor, political influence, and scientific uncertainty in shaping both market outcomes and public health policy.